Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. - Wikidata - awgldk - TriplyDB

Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.

Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.

http://www.wikidata.org/entity/Q37346737

about

The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes.

P2860

Q38205588-57721A89-5683-4DE3-982A-91D746010758 Q38690898-C62787F3-2C79-46FF-AAA8-438D4D024400

P2860

Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.

http://www.wikidata.org/entity/Q37346737

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinically relevant reductions ...... s four studies of saxagliptin.

@en

Clinically relevant reductions ...... s four studies of saxagliptin.

@nl

type

label

Clinically relevant reductions ...... s four studies of saxagliptin.

@en

Clinically relevant reductions ...... s four studies of saxagliptin.

@nl

prefLabel

Clinically relevant reductions ...... s four studies of saxagliptin.

@en

Clinically relevant reductions ...... s four studies of saxagliptin.

@nl

P1433

Q37346737-95E3A590-1959-454A-A617-2505C1221907

P1476

Q37346737-5985C26E-9857-455A-8543-B48A8EC93404

P2093

Q37346737-400B8DD3-22F1-4601-97A1-7FA075F0F51A

Q37346737-42C6279A-92EE-46E9-9F34-8D4FB2F69E62

Q37346737-79FD425C-5C2A-4889-9CF5-16947FABEBA6

P2860

Q37346737-03AE10E3-1395-4732-A790-2CC445DD5F36

Q37346737-099058C3-3E0C-49C3-9B7C-23279107B934

Q37346737-0BE542DC-8157-496D-BE94-F0924D447560

Q37346737-0E14BD54-5928-4265-8B66-8BDCE671A329

Q37346737-0F417874-B400-4AA2-89C9-E934E550D7C6

Q37346737-11A371E0-41B4-48D0-9B20-F5F3E2DC6D18

Q37346737-26967BCB-ABE2-4653-BF66-D47BFF817A44

Q37346737-3AAC2924-12F0-4D96-A52F-58B8864A58CF

Q37346737-41F00E81-6325-4B1D-B654-9063D33A4097

Q37346737-4E9339D0-3190-4B1C-B4FA-1ADC1A2739E9

P304

Q37346737-4844A900-6BE2-42B6-BBCD-D84A5C1B4CEE

P31

Q37346737-9E81BB82-899D-4F56-9DE1-9D99213254B3

Q37346737-b7f150c2-c392-495e-8b3f-0ac5bb96c78e

P356

Q37346737-77913F04-800D-4A1F-8490-5ECE91261793

P433

Q37346737-FFBE0930-3CB9-4545-9B3D-77BE50DD9621

P478

Q37346737-F543CEA8-A234-4D46-AB0D-760C66D8682A

P577

Q37346737-08506A93-09A6-4F1F-84B4-DE993755EDFB

P5875

Q37346737-91FC4968-73FB-4888-AFE9-F9C6BFF8370D

P698

Q37346737-9BEB81BB-2D5F-4918-80B1-AB88CC9BC1CF

P921

Q37346737-DFD12926-0EE2-4405-B666-F1FAF9438293

P932

Q37346737-E9A7CBD1-F42C-4170-8348-65F46AE25BF0

P356

P1433

International Journal of Clinical Practice

P1476

Clinically relevant reductions ...... s four studies of saxagliptin.

@en

P2093

C S Karyekar

http://www.w3.org/2001/XMLSchema#string

R Frederich

http://www.w3.org/2001/XMLSchema#string

S Ravichandran

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

10-year follow-up of intensive glucose control in type 2 diabetes

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.

A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

P304

759-767

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJCP.12212

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

241696071

http://www.w3.org/2001/XMLSchema#string

P698

23795975

http://www.w3.org/2001/XMLSchema#string

P921

P932

3842088

http://www.w3.org/2001/XMLSchema#string